Nerlynx (neratinib) is a small molecule pharmaceutical. Neratinib was first approved as Nerlynx on 2017-07-17. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2. In addition, it is known to target epidermal growth factor receptor. Nerlynx's patents are valid until 2031-07-18 (FDA).
|Drug Class||Tyrosine kinase inhibitors|